NanoLogix Files Five Patents for Ultra Fast BioNanoChannel(TM) Diagnostic Technology, Prepares for Commercialization
May 24 2007 - 2:22PM
PR Newswire (US)
SHARON, Pa., May 24 /PRNewswire-FirstCall/ -- NanoLogix, Inc. (Pink
Sheets: NNLX) announced today that it has filed a total of 5
patents (2 U.S., 2 provisional U.S. and 1 international) for its
BioNanoChannel(TM) Technology for rapid bacterial detection and
identification. This is a unique technology developed by NanoLogix
that allows for the identification of bacteria strains in minutes
to hours in comparison to normal 1 to more days for conventional
methods such as Petri dishes. The current Petri Dish market alone
is a multi billion dollar industry. The BioNanoChannel(TM)
technology utilizes extremely small (2 to 25 Microns) channels to
trap bacteria and then applies proprietary NanoLogix techniques
covered in the patent applications to detect and or identify the
bacteria in extremely small concentrations down to a single cell.
In hospitals quick identification of bacteria can be a matter of
life or death, and doctors are forced to use damaging broad
spectrum antibiotics until the infection is identified. The
BioNanoChannel(TM) technology is simple and user-friendly (doesn't
need sophisticated opto-electronic equipment), and is applicable to
a large number of different liquid, solid, and bioaerosol samples.
The apparatus excluding a microscope can be held in one's hand.
"These five patent applications are the cumulative result of eight
years of brilliant work by Dr. Sergey Gazenko, who is the world's
leading expert in the field of BioNanoChannel(TM) Technology," said
Bret Barnhizer, CEO and Chairman of NanoLogix. "We anticipate his
efforts leading to NanoLogix increasing its technology advantage in
yet another area that is separate from, but complementary to, our
efforts in hydrogen bioreactor and other medical technology
development." NanoLogix is currently finalizing the tooling for the
first production run of the BioNanoChannel(TM) device. In addition
to medical applications, there are similar needs in the food
industry and BioDefense for rapid bacteria detection and ID.
NanoLogix is in contact with the United States government in regard
to rapid, portable and affordable Anthrax identification. One
advantage the BioNanoChannel(TM) has over competing technologies
such as PCR (Polymerase Chain Reaction) is its ability to determine
whether the spores or cells are still alive, which is critical for
decontamination. Dana Allen, Vice President of Strategic Partnering
of NanoLogix, stated, "Regulatory approvals are required for the
BioNanoChannel(TM) before it can be sold in the general diagnostic
market. At this point we can sell it for research, pursue
partnering agreements, pursue grants and contract with entities
such as our government for BioDefense and other needs while we
pursue regulatory approvals. Approvals for diagnostic devices are
much easier than for drugs." About NanoLogix, Inc. NanoLogix is an
industry innovator in the research, development, and
commercialization of nano-biotechnologies, applications and
processes. The Company has developed and owns or has rights to 31
patents related to various medical technologies, 5 of which also
have hydrogen-generation aspects. In the past year the Company has
filed an additional 28 patent applications for discoveries related
to hydrogen bioreactors, medical testing, and innovative medical
treatments potentially related to leukemia and sepsis. NanoLogix is
presently operating a hydrogen bioreactor at Welch's Food.
NanoLogix-developed patents are used to design and market
diagnostic test kits for use in early detection of the bacteria
present in infectious and noninfectious human diseases such as
tuberculosis, pneumonia, HIV/AIDS, cancer, and cystic fibrosis. The
company also owns a patent for the non-toxic induction of apoptosis
('cell suicide') for the treatment of cancer. BioNanoChannel is a
Trademark of NanoLogix, Inc., for more information on the Company,
visit http://www.nanologix.net/. This press release contains
statements, which may constitute "forward- looking statements"
within the meaning of the Securities Act of 1933 and the Securities
Exchange Act of 1934, as amended by the Private Securities
Litigation Reform Act of 1995. Those statements include statements
regarding the intent, belief or current expectations of NanoLogix,
Inc., and members of its management as well as the assumptions on
which such statements are based. Prospective investors are
cautioned that any such forward-looking statements are not
guarantees of future performance and involve risks and
uncertainties, and that actual results may differ materially from
those contemplated by such forward-looking statements. The Company
undertakes no obligation to update or revise forward-looking
statements to reflect changed assumptions, the occurrence of
unanticipated events or changes to future operating results.
Contact: Contacts: Bret Barnhizer, CEO 724.346.1302 Website:
http://www.nanologix.net/ DATASOURCE: NanoLogix, Inc. CONTACT: Bret
Barnhizer, CEO of NanoLogix, Inc., +1-724-346-1302 Web site:
http://www.nanologix.net/
Copyright